BillionToOne

BillionToOne is a precision diagnostics company based in Menlo Park, California, founded in 2016. The company focuses on advancing healthcare through innovative molecular diagnostics, particularly in prenatal screening and oncology. Utilizing its proprietary Quantitative Counting Templates (QCT™) technology, BillionToOne detects and quantifies disease-related DNA fragments at the single base-pair level. The company has achieved significant milestones, including the launch of its UNITY Fetal Antigen NIPT in September 2022 and the UNITY Complete service, which has supported over 80,000 pregnant patients by April 2024. BillionToOne has received various funding rounds, including a $130 million Series D in June 2024, and has been recognized for its workplace culture. With a mission to make high-accuracy testing more efficient and accessible, BillionToOne is positioned at the forefront of precision molecular diagnostics.